Canada markets closed

Royalty Pharma plc (RPRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
28.09+0.12 (+0.43%)
At close: 04:00PM EDT
28.40 +0.31 (+1.10%)
After hours: 06:47PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close27.97
Open28.50
Bid28.04 x 200
Ask28.10 x 800
Day's Range28.04 - 28.59
52 Week Range25.92 - 35.09
Volume2,846,051
Avg. Volume2,853,266
Market Cap16.782B
Beta (5Y Monthly)0.47
PE Ratio (TTM)11.10
EPS (TTM)2.53
Earnings DateAug 06, 2024 - Aug 12, 2024
Forward Dividend & Yield0.84 (3.00%)
Ex-Dividend DateMay 16, 2024
1y Target Est45.50
  • GuruFocus.com

    Royalty Pharma PLC (RPRX): A Strategic SWOT Insight

    Decoding the Financials and Future Prospects in Royalty Pharma's Latest 10-Q Filing

  • GlobeNewswire

    Royalty Pharma Reports First Quarter 2024 Results

    Royalty Receipts growth of 14% driving Portfolio Receipts of $717 millionNet cash provided by operating activities of $665 millionFull year 2024 guidance confirmed: Portfolio Receipts expected to be $2,600 to $2,700 millionCommitment to grow dividend by mid-single digit percentage annually NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2024 and confirmed full year 2024 guidance for Portfolio Receipts. “We con

  • GlobeNewswire

    Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab

    Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseasesExpands Royalty Pharma’s development-stage portfolio to 15 therapies with the combined potential to generate significantly greater than $1 billion in annual peak royalties Royalty Pharma to highlight the strength of its development-stage pipeline on its first quarter of 2024 financial results call today at 8:00 a.m. NEW YORK, May 09, 2024 (GLOBE NEWSWIR